Ten year experience with induction therapy in locally advanced non-small cell lung cancer (NSCLC): Is clinical re-staging predictive of pathological staging?

Stefano Margaritora, Alfredo Cesario, Domenico Galetta, Antonio D'Andrilli, Giuseppe Macis, Giovanna Mantini, Lucio Trodella, Pierluigi Granone

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To verify if in our experience with 'induction therapy' in non-small cell lung cancer (NSCLC) the clinical re-staging is really predictive of pathological staging. Materials and methods: From January 1990 to February 2000, 136 patients with locally advanced NSCLC underwent a protocol of induction therapy according to three different treatment plans: Carboplatin+radiotherapy - study A; Cisplatin+5-Fluorouracil+radiotherapy - study B; Gemcitabine+radiotherapy - study C. Results: Clinical re-staging showed in the patients enrolled in study A a clinical Complete Response rate (cCR) of 2.3%; a clinical Partial Response rate (cPR) of 50%; a clinical Stable Disease (cSD) rate of 44.3%; a clinical Disease Progression (cDP) rate of 3.4%. In study B, cCR was 0%; cPR: 71.4%; cSD 10.7%; cDP: 17.9%. In study C, cCR was 0%; cPR: 23.5%; cSD: 11.8%; cDP: 64.7%. After clinical re-staging, 76 patients (47 group A; 23 group B; 6 group C) were judged to be resectable and underwent a surgical operation. Pathological staging showed no tumour in eight patients (10.5%; 8/76) (three in study A, four in study B, one in study C) and microscopic neoplastic remnants in seven (9.2%; 7/76). Thirty-nine patients were pN0. Overall downstaging rate in the operated patients was 51%. No precise correlation was found among clinical re-staging and pathological staging. We had two cCRs and eight pCRs, and all of these pCRs had been re-staged as cPR except in one case (cSD). In seven cases, where only microscopic remnants have been found, six had been clinically restaged as cPR and one as cSD. Conclusions: Our experience confirmed how often the clinical re-staging data are unreal. Accordingly surgery should be indicated in any case where an induction therapy has been administered, if it is reasonably possible.

Original languageEnglish
Pages (from-to)894-898
Number of pages5
JournalEuropean Journal of Cardio-thoracic Surgery
Volume19
Issue number6
DOIs
Publication statusPublished - 2001

Keywords

  • Clinical restaging
  • Clinical staging
  • Induction therapy
  • Non-small cell lung cancer
  • Pathological staging

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Fingerprint

Dive into the research topics of 'Ten year experience with induction therapy in locally advanced non-small cell lung cancer (NSCLC): Is clinical re-staging predictive of pathological staging?'. Together they form a unique fingerprint.

Cite this